141 results about "Sorafenib" patented technology

The invention relates to the field of biological medicine, in particular to IMSFs hydrogel, a ferroptosis induction system, a preparation method and application. The IMSFs hydrogel comprises a hydrogel body, and ferroferric oxide nanoparticles and sorafenib are loaded in the hydrogel body in a wrapping manner. The IMSFs hydrogel can be used as an injectable cascade ferroptosis anti-cancer drug. The preparation method of the IMSFs hydrogel comprises the following steps: firstly, preparing a silk fibroin-hyaluronic acid hydrogel body: dissolving silk hydrogel and hyaluronic acid in a lithium bromide solution; bDDE is added into the dissolved solution, and incubation is carried out; then dialyzing and washing with deionized water to obtain a silk fibroin-hyaluronic acid hydrogel body; and then loading the sorafenib nanoparticles and the ferroferric oxide nanoparticles into the silk fibroin-hyaluronic acid hydrogel body. The IMSFs hydrogel disclosed by the invention integrates magnetic thermal response and drug controlled release, and can be injected to a tumor site, so that the treatment effect on TNBC is remarkably improved.

The present invention provides a multi-modal model construction method and system for predicting the efficacy of sorafenib in hepatocellular carcinoma. The method comprises: step 1, collecting clinical information of a target patient, and generating a whole slide image; step 2, preprocessing clinical data, and retaining clinical features as input for a multi-modal deep learning model; step 3, preprocessing the whole slide image; step 4, constructing an image model, acquiring patch-level scores of the pathological image on the basis of the preprocessed image and by using different aggregation algorithms, and predicting the score of the whole pathological image to obtain best model features; step 5, constructing a multi-modal model, performing modal fusion on the best model features and the clinical features, and outputting an image-level or patient-level prediction result; and step 6, testing and evaluating the model. The present invention achieves bimodal input of a pathological image and clinical information, fully utilizes the complementarity of the two types of modal data, and thus improves prediction accuracy.

The invention discloses a sulfatase-driven polypeptide condensate with a chemotherapy sensitization effect and a preparation method thereof, and belongs to the field of biological medicines. According to the principle that sulfatase can catalyze hydrolysis of sulfate bonds, main polypeptide YSO4F responded by sulfatase enzyme is designed and synthesized; and the enzyme response aggregate m-YSO4F-LSG is blended with a protein G3BP2 ligand FGDF-YSO4F to prepare the enzyme response aggregate m-YSO4F-LSG with a sorafenib chemosensitization effect. Tumor cells can generate stress particles with a chemotherapy drug resistance effect under the stimulation of a chemotherapy drug sorafenib, the treatment effect of the sorafenib is weakened, and the protein G3BP2 is one of core proteins of the stress particles. After the m-YSO4F-LSG enters tumor cells, sulfate groups are hydrolyzed under the catalytic action of sulfatase overexpressed in tumor cell lysosomes, so that phase separation liquid drops d-YF-LSG with high affinity to protein G3BP2 are formed in the cells in situ, the phase separation liquid drops d-YF-LSG act with the protein G3BP2 and are fused with stress particles, chemotherapy drug resistance generated by the stress particles is inhibited, and the chemotherapy effect is improved. The treatment effect is improved.

The invention discloses a microneedle patch loaded with a sorafenib and copper-doped Prussian blue nano material and application of the microneedle patch in in-situ triple-negative breast cancer treatment. The sorafenib and the copper-doped Prussian blue nano material are loaded in a needle body of the microneedle patch. The microneedle patch can accurately deliver nanoparticles and sorafenib to tumor tissues, the chemical kinetics effect is enhanced through an efficient and mild photothermal therapy, the ferroptosis of triple negative breast cancer cells is enhanced through ferroptosis induced by the nanoparticles and sorafenib in cooperation with drugs, then cell death is induced, and the curative effect is improved. And a brand-new and promising treatment method is provided for in-situ triple-negative breast cancer treatment.

The invention discloses an application of a pharmaceutical composition of erianin (ERI) and sorafenib (SOR) in preparation of an anti-liver cancer drug. The invention further discloses a pharmaceutical composition which comprises ERI and SOR, and the specific molar ratio of ERI to SOR is optimized and determined through an in-vitro experiment. The composition is developed based on multi-mode screening (network pharmacology prediction, molecular docking and molecular dynamics simulation) of STAT3 targets, and in-vitro experiments prove that the composition has synergistic anti-tumor activity and can be used for preparing anti-liver cancer drugs. The invention further discloses a development method of the ERI-SOR composition integrated with multi-mode computational simulation. Experiments prove that ERI and SOR both show a remarkable synergistic effect (combination index (CI) lt, 1) at the concentration of 0.5-16 [mu] M, CI at the optimal ratio (1: 1, 4 [mu] M + 4 [mu] M) reaches 0.617, the cell proliferation inhibition effect is remarkable compared with that of a single drug, and the excellent synergistic effect is shown.

The invention relates to a structure, synthesis and application of morpholine ring oligonucleotide. A morpholine ring oligonucleotide structure is named Mo-CEBPA, can induce intracellular redox imbalance and trigger ferroptosis by inhibiting expression of CEBPA in hepatoma carcinoma cells, can assist sorafenib in killing hepatoma carcinoma cells, and overcomes the defect that existing drugs cannot efficiently induce hepatoma carcinoma cell ferroptosis.

The invention discloses an NIR-II emitted J aggregation-induced emission photosensitizer, a pharmaceutical composition constructed by the photosensitizer, a preparation method and application of the photosensitizer. The photosensitizer can generate cytotoxic I-type active oxygen under illumination, and has excellent NIR-II region fluorescence imaging capability and phototherapy performance. The photosensitizer is further assembled with sorafenib to form a pharmaceutical composition, and the pharmaceutical composition has a J aggregation-induced secondary self-assembly characteristic, realizes long-time imaging at a tumor site, exerts dual functions of NIR-II region fluorescence imaging and tumor treatment, and is good in stability, low in toxic and side effects and wide in clinical application prospect. # imgabs0 #

The invention discloses a sorafenib-paclitaxel combined prodrug as well as a preparation method and application thereof, and relates to the field of chemical pharmacy, a prodrug strategy is utilized, sorafenib and paclitaxel are covalently linked through a disulfide bond, and an S-PTX drug is successfully prepared. The drug can be self-assembled to form stable nanoparticles in an aqueous solution system containing 1% of absolute ethyl alcohol and 1% of polyoxyethylated castor oil by means of hydrophobic interaction, Van der Waals force and the special chemical properties of disulfide bonds. According to the invention, the drug delivery is carried out without any additional carrier, so that the problem of carrier toxicity when the carrier is introduced into the traditional nano delivery system is avoided, the safety of the drug in in-vivo application is greatly improved, and a solid and reliable foundation is provided for subsequent clinical treatment. The sorafenib-paclitaxel combined prodrug S-PTX prepared by the invention effectively solves the problem of drug resistance caused by medication of a single drug.

The invention provides a preparation method of a hybrid cell membrane modified nano-drug for inhibiting interment of macrophages. According to the invention, a multifunctional bionic nano-drug with a'core-shell 'structure is prepared from liver cancer cell membrane and bone marrow-derived macrophage membrane hybrid double-drug-loading carrier nanoparticles. In the application, the bionic function of macrophages is firstly realized, so that the drug is prevented from being swallowed by mononuclear macrophages in vivo, and the side effect of the drug is reduced; secondly, by utilizing the homologous targeting effect of hepatoma carcinoma cells of Hepa1-6, the aggregation of the medicine in tumors is enhanced, and the utilization efficiency of the medicine is improved; finally, the two drugs including sorafenib and Xkr8siRNA are co-delivered, so that the pharmacokinetics is simplified, and the immunotherapy effect of the liver cancer can be promoted by utilizing the inhibition of the Xkr8siRNA on the intercellular effect.

The invention provides a pharmaceutical composition for treating MSS intestinal cancer, and belongs to the technical field of biological medicine, the pharmaceutical composition is used for deeply researching a treatment scheme for effectively inhibiting the MSS intestinal cancer, carrying out basic research from protein purification, proteomics, siRNA libraries and the like, and trying to develop a brand new treatment scheme and a treatment mode using nitixinone, sorafenib and PD1 antibodies; the three medicines are combined for use, so that a remarkable synergistic effect is achieved, and the tumor is successfully changed from cold to hot. The pharmaceutical composition provided by the invention has an important clinical value, breaks through the current difficulty in treatment of MSS intestinal cancer, and opens a brand new direction of application of immunotherapy in clinical advanced metastatic colorectal cancer.

The invention discloses an application of a medicine cobimetinib (cobimetinib) in inhibiting the activity of a YAP-TEAD transcription complex, and relates to the field of medicine application. The invention relates to an application of cobimetinib (cobimetinib) and sorafenib (sorafenib) in the prevention of the drug tolerance of the liver cancer to the sorafenib (sorafenib) through the combined use of the cobimetinib and the sorafenib (sorafenib). According to the cobimetinib disclosed by the invention, the cobimetinib can be used for inhibiting the occurrence and the development of YAP highly activated tumors by targeting a YAP-TEAD transcription complex, so that the adaptation disease range of the cobimetinib is expanded; according to the present invention, the activity of the YAP is inhibited through the cobimetinib in the targeting manner, such that the drug tolerance of the liver cancer on the sorafenib can be prevented;

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.

The invention belongs to the field of biological medicine, and particularly relates to a fusobacterium nucleatum FtsZ protease inhibitor and application thereof. On the basis of the idea of new use of old drugs, drugs approved by FDA are subjected to structure-based virtual screening and molecular dynamics simulation, and sorafenib, ponatinib, ceritinib and ibastine can be stably combined to active sites of fusobacterium nucleatum FtsZ protease; in-vitro experiments also show that sorafenib, ponatinib, ceritinib and ibastine are inhibitors with the fusobacterium nucleatum FtsZ protease, so that new antibacterial applications of sorafenib, ponatinib, ceritinib and ibastine are explored. The invention not only provides a new angle for antibiotic discovery, but also provides an example for rapid development of a novel FtsZ protease inhibitor.

The invention discloses application of sorafenib in maintenance treatment of acute myelogenous leukemia after transplantation, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: it is found for the first time that secretion and killing functions of NK cells can be enhanced by using sorafenib for maintenance treatment after transplantation; sorafenib enhances communication between macrophages and NK cells by promoting secretion of macrophage proinflammatory factors, so that the function of NK cells is enhanced. The invention clarifies that sorafenib enhances the GVL effect of NK cells in a low tumor load environment, discusses the molecular mechanism of sorafenib for enhancing the NK cell function by promoting macrophage metabolism reprogramming, and provides a new thought for maintaining precision and optimization of treatment after transplantation.

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.

The invention provides application of combination of an HSP70 inhibitor and sorafenib in treatment of mTOR activated liver cancer, and belongs to the technical field of drug combination. According to the invention, the HSP70 inhibitor is used as a sorafenib sensitizer, so that the drug resistance of hepatoma carcinoma cells to sorafenib caused by activation of mTOR is overcome, the sensitivity of the mTOR activated hepatoma carcinoma cells to sorafenib is improved, and the occurrence of ferroptosis is promoted, thereby enhancing the anti-tumor effect of sorafenib.

The invention relates to the field of compounds and biological medicines, and discloses ROS (reactive oxygen species) responsive siRNA (small interfering Ribonucleic Acid) nano-micelles as well as a preparation method and application thereof. According to the invention, a polymer synthesized by adopting a TK-GUA monomer with guanidyl is tightly combined with siRNA through electrostatic interaction, a hydrogen bond and a stable salt bridge structure. Under the action of high-concentration ROS, the ROS response type siRNA nano-micelle disclosed by the invention can be subjected to responsive splitting, so that efficient release of siRNA is realized. Wherein the polymer B has remarkable ROS responsiveness and can trigger release of siRNA under the action of 5 mM hydrogen peroxide, and the regulation and control capability of the polymer B is superior to that of the prior art. The siRNA polymer nano-micelle disclosed by the invention can be combined with sorafenib to realize a synergistic anti-tumor effect.

This invention discloses a eucalyptane-type sesquiterpene dimer compound, its preparation method, and its applications, belonging to the field of pharmaceutical preparation technology. The six eucalyptane-type sesquiterpene dimers (compounds 1-6) disclosed in this invention are novel compounds with defined stereostructures and optically pure composition, exhibiting varying degrees of cytotoxic activity against HepG2, Hep3B, and Huh7 cells. Using sorafenib as a positive control, compounds 1, 5, and 6 showed stronger cytotoxic activity against HepG2 cells than the positive control sorafenib, compound 5 exhibited the strongest cytotoxic activity against Hep3B cells, and compounds 1, 4, 5, and 6 showed stronger cytotoxic activity against Huh7 cells than the positive control sorafenib. Therefore, compounds 1-6 disclosed in this invention have the potential to be developed into anti-hepatocellular carcinoma drugs, showing promising application prospects, and also provide important theoretical support for the further development of Atractylodes macrocephala medicinal plant resources.

The present invention discloses a tumor-activated sorafenib prodrug, its preparation method, and its application, belonging to the field of biomedicine technology. The present invention designs a tumor-activated sorafenib prodrug, composed of sorafenib and ferrocenecarboxylic acid molecules as its main structure. It can specifically activate cytotoxicity at the tumor site, and compared to sorafenib, it is more effective in killing liver cancer cells. Furthermore, it undergoes an in situ Fenton reaction, generating oxygen to alleviate tumor hypoxia and reduce tumor invasion and migration. The Fenton reaction can generate highly toxic hydroxyl radicals, which kill liver cancer cells and provide auxiliary treatment.

The invention provides a pharmaceutical composition and application thereof in preparation of medicines for treating tumors. The pharmaceutical composition comprises the orbitrazine fumarate, a second active agent and pharmaceutically acceptable auxiliary materials. The second active agent comprises at least one of tamoxifen, irinotecan hydrochloride, sorafenib, cis-platinum, doxorubicin hydrochloride, paclitaxel and etoposide. The scheme provided by the invention has a remarkable synergistic anti-tumor effect, and a combined medication scheme is expected to provide a safer and more effective treatment choice for tumor patients, so that the pharmaceutical composition has an important clinical application value.

Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

The application discloses a novel metabolic marker for preparing a medicine for treating liver cancer and application thereof. By constructing an ALDH6A1 overexpression liver cancer cell line, it is found through detection that the level of methylcitrate in the cell is inversely proportional to the proliferation and migration rate of liver cancer cells. In Aldh6a1 knockout mice, an AKT / NRAS liver cancer model is constructed by high-pressure tail vein injection, and it is found that the content of methylcitrate in the serum is inversely proportional to the levels of ALT and AST in the serum of the mice and inversely proportional to the liver cancer load of the mice. The metabolite methylcitrate can not only effectively inhibit the proliferation of liver cancer cells alone, but also can enhance the inhibitory effect of sorafenib on the proliferation of liver cancer cells. The metabolite can effectively inhibit the formation of tumors, can be used as a metabolic marker for detecting liver cancer, and can more accurately and efficiently judge the severity of liver cancer; and can be used as a novel metabolite for treating liver cancer, and can improve the treatment effect of liver cancer.

This invention discloses the application of epinodoxine in combination with sorafenib in the preparation of drugs for treating liver cancer. Experimental results show that epinodoxine significantly inhibits the proliferation of liver cancer cells and exhibits a good synergistic effect when used in combination with sorafenib, thus reducing toxicity and enhancing sensitization.

The invention relates to a viFSP1 and sorafenib combined ferroptosis enhanced liver cancer treatment system based on bionic nanoparticles as well as preparation and application of the viFSP1 and sorafenib combined ferroptosis enhanced liver cancer treatment system, belongs to the field of electrochemical energy storage and new energy materials, and discloses a bionic nano delivery system for combined use of an FSP1 inhibitor viFSP1 and sorafenib. Ferroptosis is induced by targeting liver cancer cells and M2 type tumor-related macrophages so as to improve the treatment effect of sorafenib, and the immunosuppressive tumor microenvironment is effectively reversed, so that an efficient treatment method of liver cancer is realized.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-D]pyrimidin-5-yl)phenol as an active ingredient. It has been ascertained that the present invention inhibits the formation of mammospheres in a breast cancer cell line and, when compared to anticancer drugs sorafenib and etoposide, which are topoisomerase inhibitors widely used in lung cancer, ovarian cancer, colon cancer, melanoma and the like, exhibits remarkable effects greater than or equal to those of the anticancer drugs sorafenib and etoposide. In addition, a compound of example 1, according to the present invention, exhibits synergistic anticancer effects when combined with radiotherapy or other anticancer drugs in a breast cancer cell line and a liver cancer cell line, and thus can be developed as an anticancer drug or a food exhibiting excellent effects in the treatment of cancer.

A probiotic composition for treating or preventing metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma(MASLD-HCC) or colorectal cancer, comprises one or more microbiota selected from a group consisting of Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus rhamnosus GG, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis, Streptococcus thermophilus or any combination thereof. The probiotic composition demonstrates improved therapeutic effects when combined with low-dose Sorafenib for MASLD-HCC and outperforms 5-Fluorouracil in colorectal cancer models.

The invention relates to a drug combination of annona squamosa lactone compounds and sorafenib (SF), which is characterized in that four common human hepatoma cell lines HepG2, HuH7, MHCC97H and HCCLM3 are used as research objects, and the drug combination effect among different components is evaluated by using an MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 3-diphenyltetrazolium bromide) method and Synergy Finder software. The combination of the compound and SF shows an obvious synergistic inhibition effect on the growth of hepatoma carcinoma cells, and meanwhile, the pharmaceutical composition can synergistically reduce the ATP level of the hepatoma carcinoma cells and induce hepatoma carcinoma cell apoptosis. Pharmacodynamic experiments show that the compounds annonacin and SF can synergistically inhibit tumor growth and induce tumor cell apoptosis, and have no obvious toxicity to normal organs of nude mice at a low dosage. In addition, transcriptome analysis predicts that the anti-liver cancer target of the annonacin is possibly related to the SLC33A1 gene. The method can be used for preparing anti-hepatoma drugs and researching related mechanisms. The annona lactone compound disclosed by the invention is derived from annona montana Macf. Which is an annona plant, namely annona montana Macf.

The invention provides a medicine containing helenin C and sorafenib for treating cancers. The medicine comprises helenin C and sorafenib. Compared with the prior art, the medicine for treating cancer provided by the invention has the advantages that the composition of the helenin C and the sorafenib has remarkable anti-cancer activity and synergistic effect, the cancer can be more effectively treated, and meanwhile, the toxic and side effects are reduced.

The invention discloses a targeted modified type co-drug-loading liposome and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the drug-loading liposome comprises phospholipid, cholesterol, a targeted ligand and an anti-hepatic fibrosis drug, the targeted ligand comprises one of vitamin A, hyaluronic acid, glycyrrhetinic acid and sialic acid, and the anti-hepatic fibrosis drug comprises one of phospholipid, cholesterol and anti-hepatic fibrosis drugs. The anti-hepatic fibrosis medicine is prepared from artesunate and sorafenib. The drug-loaded liposome prepared by the invention can actively target the hepatic stellate cells through a receptor-ligand specific binding effect, so that the uptake efficiency of the hepatic stellate cells is improved. The artesunate and the sorafenib are released in cells, redox imbalance in the cells is caused by the synergistic effect of the artesunate and the sorafenib, hepatostellate cells are induced to generate ferroptosis, and therefore efficient anti-fibrosis treatment is achieved.